Clinical Trials Logo

Allergic Conjunctivitis clinical trials

View clinical trials related to Allergic Conjunctivitis.

Filter by:

NCT ID: NCT01107405 Completed - Clinical trials for Allergic Conjunctivitis

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in a modified Conjunctival Allergen Challenge model and in an environmental model during pollen season. Comparisons will be made following 2 weeks of dosing.

NCT ID: NCT01037179 Completed - Clinical trials for Allergic Conjunctivitis

An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

Start date: February 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.

NCT ID: NCT01012752 Not yet recruiting - Allergic Rhinitis Clinical Trials

A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts

Start date: October 2016
Phase: Phase 3
Study type: Interventional

This trial is performed to evaluate the safety and clinical efficacy of subcutaneous specific immunotherapy in patients suffering from seasonal allergic rhinitis/rhinoconjunctivitis.

NCT ID: NCT01001091 Completed - Clinical trials for Allergic Conjunctivitis

AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.

NCT ID: NCT00987272 Completed - Clinical trials for Allergic Conjunctivitis

Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects

Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate safety and efficacy of Olopatadine 0.2% compared to its vehicle in Japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge (CAC) test.

NCT ID: NCT00982163 Completed - Clinical trials for Allergic Conjunctivitis

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

Start date: August 2008
Phase: N/A
Study type: Observational

The study was designed to evaluate the pattern of seasonal allergic signs and symptoms consistent with ongoing ocular allergic inflammation during ragweed season. It was hypothesized that a pattern of ongoing ocular allergic inflammation existed in certain subjects.

NCT ID: NCT00889330 Completed - Clinical trials for Allergic Conjunctivitis

Safety and Efficacy Study of a Eye Drop for Eye Allergy

Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.

NCT ID: NCT00889252 Completed - Clinical trials for Allergic Conjunctivitis

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers.

NCT ID: NCT00882687 Completed - Clinical trials for Allergic Conjunctivitis

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

Start date: April 24, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis

NCT ID: NCT00881673 Withdrawn - Clinical trials for Allergic Conjunctivitis

To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen Challenge (CAC).